ISRCTN74112318
Completed
Phase 3
A prospective randomised phase III study of observation versus screening MRI and preemptive treatment in castrate resistant prostate cancer patients with spinal metastasis
Institute of Cancer Research Experimental Cancer Medicine Centre0 sites541 target enrollmentNovember 29, 2012
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Institute of Cancer Research Experimental Cancer Medicine Centre
- Enrollment
- 541
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Results article in https://pubmed.ncbi.nlm.nih.gov/35279270/ (added 14/03/2022)
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Histologically / cytologically confirmed adenocarcinoma of the prostate or clinical diagnosis of prostate cancer with osteoblastic bone metastases and Prostate\-specific antigen (PSA) \= 100ng/ml
- •2\. Castrate resistant disease\*
- •3\. One or more spinal metastasis on imaging (technetium bone scan with confirmatory X\-ay as appropriate clinically) undertaken at any time during the patient?s illness
- •4\. Life expectancy of 6 months or more
- •5\. Eastern Cooperative Oncology Group (ECOG) performance status 02
- •6\. Written, informed consent
- •\*(rising PSA (\> 5 ng /ml and \>50% rise from nadir) after luteinizing hormone releasing hormone agonist (LHRHa) therapy or orchidectomy with or without antiandrogen)
Exclusion Criteria
- •1\. Back pain related to metastatic cancer, requiring regular (daily) analgesics
- •2\. Previous active malignancy within the last 5 years other than basal cell carcinoma or low grade superficial bladder cancer
- •3\. Current or previous spinal cord compression (SCC) or neurologic deficit
- •4\. Brain metastasis
- •5\. Spinal MRI within last 12 months
- •6\. CT or PET CT scan of thorax AND abdomen within the last 6 months
- •7\. Previous external beam radiotherapy to the vertebra or spinal surgery with the primary aim to prevent or treat SCC\+
- •8\. Serious or uncontrolled coexistent non\-malignant diseases
- •9\. Any contra indications for MRI
- •10\. Inability to comply with neurologic and Quality of Life (QoL) assessments
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Avastin® Randomised Trial with neo-adjuvant chemotherapy for patients with early breast cancerEarly breast cancerCancerMalignant neoplasm of the breastISRCTN68502941Cambridge University Hospitals NHS Foundation Trust (UK)800
Recruiting
Not Applicable
TEAM II A randomised, multicentre, prospective, phase III trial investigating TEAM IIa: Neoadjuvant hormonal therapy with exemestane for three versus six months. and / or TEAM IIb: The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone receptor positive early breast cancer.Breast Cancer, Neoadjuvant hormonal therapy, Aromatase inhibitor, Adjuvant therapy, BisphosphonatesNL-OMON27856TEAM II Study Group2,478
Completed
Phase 3
Gemcitabine and Docetaxel versus Doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue SarcomasISRCTN07742377niversity College London (UCL) (UK)250
Completed
Not Applicable
A study evaluating three treatments for cracked heel skiHeel fissures (or cracks)Skin and Connective Tissue DiseasesISRCTN63765263niversity of Salford93
Completed
Phase 3
A randomised phase III clinical trial investigating the effect of Fragmin® added to standard therapy In patients with lung cancerISRCTN80812769Velindre NHS Trust (UK)2,202